TALA Philippines Boosts Financial Literacy With TALAkayan Workshops

Highlighting the significance of financial education, Tala Philippines introduced TALAkayan, a series of workshops aimed at enhancing financial knowledge.

PHINMA Properties Unveils ‘Distinctly Bacolod’ Township, Saludad

PHINMA Properties is dedicated to building homes that foster and uplift nurturing communities for Filipino families.

SM Prime’s Sustainable Developments: Bridging Lifestyle And Leisure With Sustainability

SM Prime remains a key industry partner in the Philippines, delivering innovative and sustainable lifestyle cities that enrich the quality of life for millions of people.

Back-To-School Expenses? Here Are 4 Tipid Tips To Follow

As the school year 2024-2025 prepares to begin on July 29, 2024, and conclude on April 15, 2025, families across the country are adjusting to the return of the traditional June-March school calendar.

Single-Shot Johnson & Johnson Vaccine Reveals 66% Efficacy Against Covid-19

9

Single-Shot Johnson & Johnson Vaccine Reveals 66% Efficacy Against Covid-19

9

How do you feel about this story?

Like
Love
Haha
Wow
Sad
Angry

Medical Device Company, Johnson & Johnson has announced that the Janssen Covid-19 vaccine candidate was 66% effective overall in preventing moderate to severe Covid-19 cases, four weeks after the vaccination, a statement released on Friday, January 29.

Janssen Pharmaceutical Companies has developed a single-dose Covid-19 vaccine proven to be effective to nearly 44,000 participants who get their first shot, 468 of which are symptomatic. The clinical study of its efficacy was proven in the United States -72%, Latin America -66%, and less in South Africa-57% where the variant has taken root.

The company has stated that the new Janssen’s Covid-19 vaccine had an effectiveness of 85% against severe disease conducted across all the regions in the U.S, Latin America, and South Africa –resulted from 28 days after the inoculation.

The effectiveness of the vaccine has been seen to improve after 49 days –creating no severe cases in people who were vaccinated.

During the trial, those who were inoculated are completely covered against hospitalization and death. However, there was no patient recorded who have been hospitalized or died –28 days after the citizens receive the vaccine.

“These topline results with a single-shot COVID-19 vaccine candidate represent a promising moment,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.

“A one-shot vaccine is considered by the World Health Organization to be the best option in pandemic settings, enhancing access, distribution and compliance,” Stoffels added.

If the Food and Drug Administration (FDA) approves, the Janssen Covid-19 vaccine will be distributed worldwide but with the following authorization. No final dates have been disclosed yet as to when it will finally be released in the market.

If authorized, Janssen’s single-shot vaccine can be stored for two years at -20°C (-4°F), at least three months of which can be at temperatures of 2-8°C (36°F–46°F). Unlike the two vaccines Pfizer and Moderna that require two-shot, the Janssen vaccine is given once. Also, Janssen can be stored in the same cold storage that it uses today, the company stated.

Further reports will follow as the company continues to participate in an ongoing clinical study.